SCHEMBL1734451

SCHEMBL1734451

CCN(CC)c1nc(C(N)=O)cc(-c2cccc(NC(C)=O)c2)n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.69
PARP1 P09874 1/20 0.47
DHODH Q02127 1/20 0.47
SMN1; SMN2 Q16637 5/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
FYN P06241 2/20 0.46
TP53 P04637 2/20 0.46
STAT1 P42224 1/20 0.46
CNR1 P21554 1/20 0.46
ALDH1A1 P00352 5/20 0.45
BRAF P15056 4/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
GAA P10253 1/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
PI4K2A Q9BTU6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1733513 0.82 KDM4E (0.77) KDM4EPARP1DHODHSMN1; SMN2NPC1
SCHEMBL1733607 0.82 KDM4E (1.00) KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL1733687 0.81 KDM4E (0.75) KDM4EPARP1NPC1RAB9ACNR1
SCHEMBL1733619 0.81 KDM4E (0.75) KDM4EFYNMEN1KMT2AMAPT
SCHEMBL1734368 0.81 KDM4E (0.53) KDM4EPARP1DHODHSMN1; SMN2ALDH1A1
SCHEMBL1734575 0.81 KDM4E (0.70) KDM4ESMN1; SMN2NPC1RAB9ATP53
SCHEMBL1735802 0.81 KDM4E (0.73) KDM4EPARP1FYNALDH1A1MEN1
SCHEMBL1734461 0.80 KDM4E (0.72) KDM4EPARP1SMN1; SMN2NPC1RAB9A
SCHEMBL1733738 0.79 KDM4E (0.70) KDM4EPARP1ALDH1A1
SCHEMBL1734527 0.79 KDM4E (0.70) KDM4EDHODHSMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US claimed
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 KDM4E 3910/4885PARP1 4251/4885DHODH 1213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.